Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data

More in Finance

• Fortinet’s stock is taking a dive after earnings. Here’s why.

  Investors are reacting negatively after the cybersecurity company published its latest financial performance metrics. The steep drop in share value reflects immediate market dissatisfaction with the reported quarterly figures. Market participants are closely evaluating the newly released corporate numbers to understand the broader implications for the firm's outlook.

  1 min read
• Alphabet reports Q3 negative free cash flow of $9.07B, worse than expected, capex of $51.36B, vs. $55.09B est., and keeps its FY capex forecast at $195B-$205B (Samantha Subin/CNBC)

  The search giant faced an immediate market backlash as shares dropped over 10% following its latest financial release. Investors reacted sharply to severe cash burn that missed Wall Street expectations, despite quarterly infrastructure spending coming in lighter than anticipated. The company nevertheless reaffirmed its massive annual investment targets.

  1 min read
• News Wrap: Fed holds interest rates unchanged as inflation remains elevated

  Central bank officials opted to maintain current monetary policy to navigate persistent economic pressures across the country. Meanwhile, high operating expenses have triggered major travel disruptions abroad, and a significant international criminal prosecution faces procedural changes following a senior jurist's death. These separate events highlight ongoing volatility in global transit and critical legal proceedings.

  1 min read